

Title (en)
BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS

Title (de)
BICYCLISCHE CB2-CANNABINOIDREZEPTOR-LIGANDEN

Title (fr)
LIGANDS DU RECEPTEUR CANNABINOIDE CB2 BICYCLIQUE

Publication
EP 1469842 A2 20041027 (EN)

Application
EP 03734818 A 20030130

Priority
• IL 0300077 W 20030130
• IL 14794102 A 20020131
• IL 0200341 W 20020502
• IL 15030202 A 20020618

Abstract (en)
[origin: WO03063758A2] The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) α -pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neuropathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.
[origin: WO03063758A2] The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel + α -pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neuropathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.

IPC 1-7
A61K 31/02

IPC 8 full level
A61K 31/661 (2006.01); **A61K 31/045** (2006.01); **A61K 31/05** (2006.01); **A61K 31/10** (2006.01); **A61K 31/12** (2006.01); **A61K 31/122** (2006.01); **A61K 31/15** (2006.01); **A61K 31/255** (2006.01); **A61K 31/277** (2006.01); **A61K 31/35** (2006.01); **A61K 31/6615** (2006.01); **A61P 1/00** (2006.01); **A61P 1/16** (2006.01); **A61P 3/10** (2006.01); **A61P 9/00** (2006.01); **A61P 9/06** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 21/00** (2006.01); **A61P 21/04** (2006.01); **A61P 25/00** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/14** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/02** (2006.01); **A61P 43/00** (2006.01); **C07C 35/31** (2006.01); **C07C 39/17** (2006.01); **C07C 39/23** (2006.01); **C07C 45/29** (2006.01); **C07C 45/54** (2006.01); **C07C 45/71** (2006.01); **C07C 49/443** (2006.01); **C07C 49/513** (2006.01); **C07C 49/657** (2006.01); **C07C 49/747** (2006.01); **C07C 49/753** (2006.01); **C07C 69/24** (2006.01); **C07C 69/30** (2006.01); **C07C 69/40** (2006.01); **C07C 69/44** (2006.01); **C07C 69/60** (2006.01); **C07C 251/44** (2006.01); **C07C 255/40** (2006.01); **C07F 9/09** (2006.01); **C07F 9/12** (2006.01)

CPC (source: EP)
A61K 31/12 (2013.01); **A61K 31/35** (2013.01); **A61P 1/00** (2017.12); **A61P 1/16** (2017.12); **A61P 3/10** (2017.12); **A61P 9/00** (2017.12); **A61P 9/06** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/00** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12); **A61P 25/04** (2017.12); **A61P 25/06** (2017.12); **A61P 25/14** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 37/02** (2017.12); **A61P 43/00** (2017.12); **C07C 39/23** (2013.01); **C07C 45/292** (2013.01); **C07C 45/54** (2013.01); **C07C 45/71** (2013.01); **C07C 49/657** (2013.01); **C07C 49/747** (2013.01); **C07C 49/753** (2013.01); **C07C 69/30** (2013.01); **C07C 69/40** (2013.01); **C07C 69/60** (2013.01); **C07C 251/44** (2013.01); **C07C 255/40** (2013.01); **C07F 9/12** (2013.01); **C07C 2602/42** (2017.04)

C-Set (source: EP)
1. **C07C 45/292 + C07C 49/657**
2. **C07C 45/54 + C07C 49/747**
3. **C07C 45/71 + C07C 49/753**

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

DOCDB simple family (publication)
WO 03063758 A2 20030807; **WO 03063758 A3 20031231**; EP 1469842 A2 20041027; EP 1469842 A4 20060426; JP 2005523259 A 20050804

DOCDB simple family (application)
IL 0300077 W 20030130; EP 03734818 A 20030130; JP 2003563454 A 20030130